Skip to main content
Premium Trial:

Request an Annual Quote

Applied Genomic Technology Capital Funds Close with $150M in Capital

NEW YORK, March 5 – With $150 million in capital commitments, Applied Genomic Technology Capital Funds has closed its first venture funds, the Cambridge, Mass., venture capital group said Monday.

AGTC Funds, which was founded by venture capital firms NewcoGen and OneLiberty Ventures, plans to finance early-stage genomics companies that focus on information, discoveries, and technology. 

Affymetrix, Compaq, and Millennium Pharmaceuticals have all become limited partners in the funds. The funds also received institutional support from Hillman Company, OneLiberty Ventures, and Paine Webber Group. 

"Publication of the complete human genome sequence intensifies a world-wide race to develop genomic applications," Noubar Afeyan, AGTC Funds managing partner, said in a statement. “In addition to the sequence data itself, many new technologies have emerged for harnessing genomic information. The combination of open source codes and genomic tools will enable new applications in many industries, including health care, agriculture, materials, nanotechnology, energy, environmental and computing." 

AGTC Funds has already invested in four companies, AnVil Informatics, Genomics Collaborative, Hypnion, and Nanostream. AnVil, based in Lowell, Mass., is a bioinformatics company that offers data mining and visualization software for genomics research. Genomics Collaborative of Cambridge, Mass., has collected DNA and tissue samples for disease-gene association studies. Hypnion, based in Worcester, Mass., is a gene-based drug discovery that is developing new treatments for sleep disorders. Nanostream of Pasadena, Calif., is developing microfluidics devices for life sciences and diagnostics.

Afeyan comes to AGTC Funds after serving as founder and former CEO of PerSeptive Biosystems, which PE Biosystems acquired in 1997, and, subsequently, as the PE corporation executive who oversaw PE's successful spinoff of Celera. 

AGTC’s other principals include Edwin Kania, a managing general partner at OneLiberty Ventures; Nancy Crowell, a former partner and managing director at Cowen & Company; David Stone, an analyst and consultant at Liberty Tree Advisors; and Leon Palandjian, a recent graduate of Harvard Medical School and former pharmaceuticals analyst.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.